



Digital Medical Insights in the Time of COVID-19



>> NOW SPEAKING: Brant Jarrett, PhD

Sr. Field Director, Mallinckrodt

Housekeeping

Questions for Presenters:

 Please submit questions throughout the presentation using the Q&A button in your control panel.

Evaluations:

• There is a Resources widget on your screen that includes a webinar evaluation. Please complete that evaluation so that we can work to ensure the highest quality presentations.

On-demand Availability of Webinar:

• This Webinar, as with all previous ones, will be available on-demand next week in the Community Portal for MAPS members.

2



>> NOW SPEAKING: Brant Jarrett, PhD Sr. Field Director, Mallinckrodt

Disclaimer

The views expressed in this Webinar are those of the presenters, and are not an official position statement by MAPS, nor do they necessarily represent the views of the MAPS organization or its members.



>> NOW SPEAKING: Brant Jarrett, PhD Sr. Field Director, Mallinckrodt

Disclaimer

The information contained in this presentation may include views or opinions. Such views or opinions are that of the presenter, and do not reflect the views of opinions of Calithera.

Introductions



CATHERINE SUNDERLIN, PHD Senior MSL Calithera Biosciences



PATRINA PELLETT, PHD VP, Medical Strategy Kernel



DAN MANNING, PHARMD Head of Field Medical Spark

5



>> NOW SPEAKING: Patrina Pellett, PhD

VP, Medical Strategy, Kernel

Webinar Agenda

OVERVIEW

- What are medical insights & why are they important?
- Medical Insights generation in the COVID-19 era
- Getting started with digitally sourced pre-insights
- Key points to consider with digital sources
- Examples of pre-insights discovered through digital sources
- Insights generation from digitally sourced pre-insights



>> NOW SPEAKING: Patrina Pellett, PhD

VP, Medical Strategy, Kernel

Webinar Objectives

WHAT YOU WILL LEARN


- How to get started with digitally-sourced pre-insights
- Digital sources to consider
- Ways that digitally-sourced pre-insights can help understand trends in your therapeutic areas & inform strategy



What are medical insights?

DEFINITION OF AN MEDICAL INSIGHT

A new information, understanding, idea or perspective on topics relevant to a company that may identify a gap, and/or inform strategy, and/or confirm pre-existing views held by the company and may result in an action where and when appropriate.





Why are medical insights important?

IDENTIFY GAPS

0

INFORM STRATEGY




Medical Affairs Professional Society (MAPS) | 2020

9



How are medical insights generated?





Where do pre-insights come from?

SCIENTIFIC EXCHANGE BETWEEN MSLS & EXTERNAL EXPERTS





Collecting pre-insights in the COVID-19 Era

LIMITED OR NO DIRECT INTERACTION WITH HCPS





Digital Sources to Gather Pre-Insights











Newsletters


Insitution Websites

Virtual Congresses

"Live" Webinars and Recorded Interviews Social Media



Getting Started with Digitally Sourced Pre-insights



1 ALIGN & PRIORITIZE WITH INTERNAL STAKEHOLDERS

Align with cross-functional teams and institutional re-entry plans (commercial, compliance, etc.)

2 IDENTIFY POTENTIAL DIGITAL SOURCES

Which media outlets are already being followed? Are HCPs on social media?

3 DEFINE HOW TO GATHER & ANALYZE

How will digitally sourced pre-insights be reported internally & analyzed?



>> NOW SPEAKING: Catherine Sunderlin, PhD

Sr. MSL, Calithera

Strategic Considerations

RELEVANCE TO STRATEGY

Do any of the collected preinsights inform medical strategy? If yes, how so?

RELEVANCE TO TACTICS

How can digitally sourced preinsights affect already planned tactics or identify opportunities for new initiatives?


Leverage pre-insights from multiple digital sources to identify trends and generate insights.

ENGAGEMENT OPPORTUNITIES

How can digitally sourced preinsights be used for relationship building and pre-meeting planning for MSLs?



Generating Insights from Digital Sources



NEW OR EMERGING TRENDS DRIVEN BY COVID-19



EMERGING DATA AND CHANGING TREATMENT PRACTICES



MSL TERRITORY TRACKING & REDEPLOYMENT PLANNING



New or Emerging Trends Driven by COVID-19



Questions to Consider: COVID-19

PATIENT IMPACT

Are patients in your therapeutic area at higher risk for COVID-19 infection and complications?

Are any COVID-19 related symptoms/complications representative of conditions from your therapeutic area?

MEDICAL PRACTICE

How has COVID-19 affected standard of care for patients in your therapeutic area?

Have institutions or clinical societies released guidelines on how to modify current treatment practices in light of COVID-19?


MEDICAL RESEARCH

How has COVID-19 affected clinical trials in therapeutic area?



Pre-Insights from Digital Sources

DERMATOLOGY & COVID-19



Medical Affairs Professional Society (MAPS) | 2020

19



>> NOW SPEAKING: Catherine Sunderlin, PhD & Dan Manning, PharmD

Identifying Insights



POTENTIAL OPPORTUNITIES

- Optimizing clinical trials during the COVID era
- Creating a better experience for patients
- Standard of Care changes organization needs to plan for



Emerging Data and Changing Treatment Practices



Questions to Consider: Emerging Data

DATA PRESENTATION

How are new data being presented in your therapeutic area?

HCP FEEDBACK

What outlets are HCPs using to react to new data?

What are the HCPs' reactions to new data?

MEDICAL PRACTICE

What trial data in your therapeutic area are changing HCP treatment practices?



>> NOW SPEAKING: Catherine Sunderlin, PhD

Sr. MSL, Calithera

Pre-Insights from Digital Sources

ONCOLOGY EMERGING DATA

Hamid Emamekhoo @HamidEmamekhoo · May 31 Fantastic discussion by @ERPlimackMD! New standard of care in treatment of metastatic #bladdercancer. #ASCO20 @BladderCancerUS

🛛 🥐 Neeraj Agarwal @neerajaiims · May 31

#ASCO20 Fantastic @asco plenary discussion by @ERPlimackMD on the Javelin bladder-100 trial. Here is her perspective: Switch maintenance (1st line Rx with avelumab) rather than treatment break is the preferred strategy after platinum based Rx in metastatic UC @BladderCancerUS Show this thread



Elizabeth Plimack, MD, explains the design and outcomes of the Phase 3 randomized Keynote 426 study



🗐 OBR Peer-Spectives Podcast Series

OBR CONFERENCE COVERAG

ASCO GU 2020: Clinical Advancements in Renal Cell Carcinoma

Robert Figlin, MD and Tian Zhang, MD discuss recent clinical findings in renal cell carcinoma presented at ASCO GU20





>> NOW SPEAKING: Catherine Sunderlin, PhD & Dan Manning, PharmD

Identifying Insights



POTENTIAL OPPORTUNITIES

- Determine HCPs' receptivity to virtual disclosures of new data
- Identify practice changing new data
- Determine if data gaps exist and how to address



MSL Territory Tracking & Redeployment Planning



>> NOW SPEAKING: Catherine Sunderlin, PhD

Sr. MSL, Calithera

Questions to Consider

HCP ACTIVITY

In what virtual platforms is your HCP participating?

HCP TOPICS OF INTEREST

On what topics/data is your HCP speaking, posting, and publishing?

ENGAGEMENT PLANNING

What are HCPs engagement preferences? Are HCPs and institutions resuming normal activities?



>> NOW SPEAKING: Catherine Sunderlin, PhD

Sr. MSL, Calithera

Pre-Insights from Digital Sources

INDIVIDUAL HCP ONLINE ACTIVITY

tompowles @tompowles1 · Apr 30 The GU cancer group at Barts Hospital recruited and treated its first research patient since the pandemic put things on hold (FGF inhibitor in bladder cancer). We're are getting there slowly . @Uromigos @DrChoueiri @montypal - where do others stand with this? $\bigcirc 8$ 15 15 0 59 <u>_</u> Tian Zhang, MD, MHS @TiansterZhang · Apr 30 We have tiers of research studies @DukeGUCancer and kept potential non-SOC treatment trials as tier 1. Slow going when we saw limited pts but just enrolled & treated a new pt on #PDIGREE today. As more pts return & surgery 🚹 in May, research will pick up. \bigcirc 1] 2 \bigcirc 7

The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma

Tian Zhang^{a,b,*}, Joyce K. Hwang^a, Daniel J. George^{a,b}, Sumanta K. Pal^c

^aDuke University, Division of Medical Oncology, Department of Medicine, Durham 27710 NC USA ^bDuke Cancer Institute Center for Prostate and Urologic Cancers, Durham 27710 NC USA ^cCity of Hope Comprehensive Cancer Center, Los Angeles, CA USA Uromigos @Uromigos Ipilimumab and nivolumab in metastatic RCC and the PDIGREE trail with Tian Zhang @TiansterZhang @brian_rini

Translate Tweet

 The
 Episode 25: Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial -...

 Open.spotify.com
 Point







>> NOW SPEAKING: Catherine Sunderlin, PhD & Dan Manning, PharmD

Identifying Insights



POTENTIAL OPPORTUNITIES

- Identify ways to engage HCPs, make territory action plans
- Determine HCPs' interests and best way to engage
- Create plans for redeploying field force



Identifying Trends from Digitally Sourced Pre-insights

PRIOF	RITIZE
-------	--------

What are organizational priorities? What should teams focus on?

COLLECT

Define method for collecting and reporting digitallysourced pre-insights. Monitor key sources.

ANALYZE

Aggregate and visualize. Look across multiple territories, pre-insights and other functions.

IDENTIFYING INSIGHTS

Keep priorities in mind and look for unexpected patterns.

REPORTING & ACTION

Customized reports to individual stakeholder needs.



Thank you. Questions?